SavedAdd your journal

Journals / Retina-Vitreus / 2019 / Cilt: 28 - Sayı: 3

Comparison of Afl ibercept and Ranibizumab Treatment in Patients with Macular Edema Secondary to Central Retinal Vein Occlusion

Santral Retinal Ven Tıkanıklığına İkincil Gelişen Maküla Ödeminde Afl ibercept ve Ranibizumab Tedavilerinin Karşılaştırılması

Akın ÇAKIR
Burak ERDEN
Selim BÖLÜKBAŞI
Alper Halil BAYAT
Mustafa Nuri ELÇİOĞLU
Pages
289–295
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The changes in BCVA and CMT were statistically signifi cant within both groups during the 6-month follow-up (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To compare the effi cacy and safety of intravitreal ranibizumab (IVR) and intravitreal afl ibercept (IVA) injections in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO)Materials and Methods: 50 eyes of 50 patients with ME due to CRVO were reviewed retrospectively.
📊
Key Findings & Data:At baseline and after every injection best-corrected visual acuity (BCVA), central macular thickness (CMT), anatomical fi ndings, edema types, intraocular pressure changes were noted from optical coherence tomography (OCT) images and patients’ fi les.Results: 25 eyes of 25 patients were studied in both groups.
💡
Conclusion & Impact:The changes in BCVA and CMT were statistically signifi cant within both groups during the 6-month follow-up (p
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To compare the effi cacy and safety of intravitreal ranibizumab (IVR) and intravitreal afl ibercept (IVA) injections in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO)Materials and Methods: 50 eyes of 50 patients with ME due to CRVO were reviewed retrospectively. The patients were divided into two groups according to the treatment they received: IVA group and IVR group. Both groups were treated with three monthly injections followedup in PRN regimen. At baseline and after every injection best-corrected visual acuity (BCVA), central macular thickness (CMT), anatomical fi ndings, edema types, intraocular pressure changes were noted from optical coherence tomography (OCT) images and patients’ fi les.Results: 25 eyes of 25 patients were studied in both groups. The groups were similar in terms of baseline characteristics (p>0,05). The changes in BCVA and CMT were statistically signifi cant within both groups during the 6-month follow-up (p

Özet

Amaç: Santral retinal ven tıkanıklığına (SRVT) ikincil gelişen maküla ödeminde (MÖ) afl ibercept (Af) ve ranibizumab (Ra) tedavilerinin etkinliklerinin ve güvenirliklerinin karşılaştırılması. Gereç ve Yöntem: SRVT’ye bağlı MÖ’i olan 50 hastanın 50 gözü geriye dönük olarak incelendi. Hastalar aldıkları tedaviye göre 2 gruba ayrıldılar; Af ve Ra grupları. Her iki grupta ardışık 3 enjeksiyon sonrası PRN rejimiyle takip edildiler. Başlangıçta ve her enjeksiyon sonrasında hastaların en iyi düzeltilmiş görme keskinlikleri (EİDGK), santral maküla kalınlıkları (SMK), anatomik bulguları, ödem tipleri ve göz içi basınç değişimleri not edildi. Bulgular: Her iki grupta da 25 hastanın 25 gözü geriye dönük olarak incelendi. Gruplar başlangıç özellikleri açısından benzerdi (p>0,05). EİDGK ve SMK değişimleri altı ay boyunca her iki grupta da istatiksel olarak anlamlıydı (sırasıyla p

🔖

Cite This Article

ÇAKIR, A., ERDEN, B., BÖLÜKBAŞI, S., BAYAT, A. H., ELÇİOĞLU, M. N. (2022). Comparison of Afl ibercept and Ranibizumab Treatment in Patients with Macular Edema Secondary to Central Retinal Vein Occlusion. Retina-Vitreus, Cilt: 28 - Sayı: 3, 289–295. https://ajindex.com/articles/589097

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Klein R, Moss SE, Meuer SM, Klein BE. (2008) The 15-year cumulative incidence of retinal vein occlusion. The Beaver Dam eye study. Arch Ophthalmol. 126:513-8.
  2. Ehlers JP, Fekrat S. (2011) Retinal vein occlusion: beyond the acute event. Surv Ophthalmol. 56:281-99.
  3. Hayreh SS, Podhajsky PA, Zimmerman MB. (2011) Natural history of visual outcome in central retinal vein occlusion. Ophthalmology.118(119–33):e1–2. Yau JW, Lee P, Wong TY, Best J, Jenkins A (2008) Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 38:904-10.
  4. Deobhakta A, Chang LK (2013) Infl ammation in retinal vein occlusion. Int J Infl am 2013:438412. Noma H, Funatsu H, Mimura T, Harino S, Hori S (2009) Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 116:87-93.
  5. Noma H, Mimura T, Masahara H, Shimada K (2014) Pentraxin 3 and other infl ammatory factors in central retinal vein occlusion and macular edema. Retina 34:352-9.
  6. Boyd SR, Zachary I, Chakravarthy U, Allen GJ,Wisdom GB, CreeIA, Martin JF, Hykin PG (2002) Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 120:1644-50.
  7. Jung SH, Kim KA, Sohn SW, Yang SJ (2014) Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion. Invest Ophthalmol Vis Sci 55:2290-6.
  8. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N,Murahashi WY, Rubio RG (2011) Sustained benefi ts from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041-9.
  9. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119:802-9.
  10. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A, RETAIN Study Group (2014) Long-term outcomes in patients with retinal vein occlusiontreated with ranibizumab: the RETAIN study. Ophthalmology 121:209-19.
  11. Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, MaY, Stemper B, Zeitz O, Sandbrink R, Haller JA (2014) Intravitreal afl ibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 121:1414-20.